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Abstract 
 The purpose of this research was to develop, construct and validate a two-compartment 
dissolution testing instrument as an alternative test methodology to the current standard USP 
apparatus II system.  The current USP apparatus II system was developed in the 1970’s and has 
known defects in its design related to fluid dynamics and bio relevance.  This two-compartment 
dissolution instrument eliminates the issues of fluid dynamic mixing, use of biorelevant media 
levels and provides clinically relevant data.  The two-compartment dissolution instrument was 
tested in conjunction with GastroPlus simulations to mimic a human model with drug absorbance 
set to zero.  This instrument was able to produce similar gastric and duodenum amount recovery 
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Chapter 1. Introduction 
1.1 Pharmaceutical Testing Overview for Solid Oral Dosage Units 
 During the lifecycle of a solid oral dosage unit, such as a capsule or a tablet, in the 
pharmaceutical industry there are multiple tests used to ensure the safety, efficacy and quality of 
the drug product.  These tests are applied to detect differences from one lot manufactured to the 
next.  The tests are applied to monitor the drug product performance in different temperatures 
and humidity conditions over time.  This thesis is focused on one specific test, the dissolution 
test.  
 The dissolution test is important as it is the only analytical test used that monitors the 
disintegration of the oral solid dosage and the dissolution of the active pharmaceutical ingredient 
in media.  The dissolution of the active pharmaceutical ingredient in media over time is known 
as the dissolution rate.  The dissolution rate is important because it can predict whether the active 
pharmaceutical ingredient will be effective or not.1 The dissolution rate can also be used to 
predict serious situations to avoid when taking the oral solid dosage.  For example, Palladone XL 
(hydromorphone hydrochloride), which is designed to be a modified release dosage form which 
means it releases the active pharmaceutical ingredient slowly over time in the digestive system, 
resulted in a six-fold increase in blood levels when ingested with alcohol.2   The presence of the 
alcohol interfered with the tablets ability to slowly release the drug over time.  This is known as 
alcohol dose dumping,2 and could result in death.    
The dissolution test is used as a quality control (QC) test,3-4 as a tool for developing a 
drug product formulation,5 and for In Vitro In Vivo Correlation (IVIVC) studies or 
bioequivalence (BE) studies.3, 6-9 The test is conducted in one of seven United States 
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Pharmacopeia (USP) approved dissolution apparatuses.10 The seven USP approved dissolution 
systems are: 
  USP Apparatus 1 – Rotating Basket 
  USP Apparatus 2 – Rotating Paddle 
  USP Apparatus 3 – Reciprocating Cylinder 
USP Apparatus 4 – Flow Through Cell 
 USP Apparatus 5 – Paddle over Disk – modification of Apparatus 2 
 USP Apparatus 6 – Rotating Cylinder – modification of Apparatus 1 
  USP Apparatus 7 – Reciprocating Holder – modification of Apparatus 3 
The most commonly used dissolution apparatus is the USP Apparatus 2 system.  The 
system was first introduced in the 1970’s.11 A picture representing a current design of the system 
is seen in Picture 1.   
 
Picture 1: Distek Evolution 6300 Paddle Configuration, USP Apparatus 2 System 
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The system consists of at least six one-liter round bottom vessels that are suspended in a hot 
water bath.  The hot water bath is kept at a steady temperature of 37.0 +/- 0.5 ℃9 (97.7 ℉ to 99.5 
℉).  The vessels are filled with 500 to 1000 mL of media as required per the analytical method 
being followed, though the most common volume used is 900 mL.12 A paddle is suspended at a 
prescribed depth of the vessel and used to mix the media at a set speed, typically between 50 to 
100 rotations per minute or RPM.12 Samples are withdrawn at certain times and analyzed for the 
percent amount of drug present in that aliquot.  The results are plotted as percent released versus 
time.  An example is shown in Figure 1 below. 
  
Figure 1: Tablet USP Apparatus II Dissolution Plot Example 
1.2 Quality Control Test Versus IVIVC 
There are two main different uses for the dissolution test.  The two uses are for quality 
control testing of the oral solid dosage unit and IVIVC testing.  The quality control test is 
developed and used to detect differences in the oral solid dosage unit from lot to lot or over time.  
The IVIVC test is developed and used to predict the oral solid dosages performance in the body 






















Example Dissolution Release Profile
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The first use is the quality control (QC) test.  The QC test is properly developed and 
validated11-13 to aid in drug product development5 as well as perform release and stability testing 
of the drug product.4 The QC test is the only analytical test that is used to detect the 
disintegration and dissolution performance of the oral solid dosage from one lot of material to 
the next.  The QC dissolution test is used to test the oral solid dosage from research through 
commercial manufacturing. 
The QC dissolution method is developed alongside formulation development of the drug 
product.  The dissolution test monitors the disintegration of the drug product as well as the 
dissolution of the active pharmaceutical ingredient in a selected media.  The media is selected 
based off knowledge of where in the digestive system the oral solid dosage is intended to 
disintegrate.  For example, if the oral solid dosage is intended to disintegrate in the stomach, then 
a gastric media is used for the dissolution test.  From there the test is developed using guidelines 
from the USP on development of the test (apparatus to use, running parameters to begin with).   
Ideally the test is developed with multiple lots of the oral solid dosage that has been 
prepared slightly differently by the formulation scientists.  For example, one lot of tablets could 
be pressed harder, another could have a larger layer of coating applied.  Both of which would 
modify the disintegration parameters of the oral solid dosage and thus impact the release of the 
active pharmaceutical ingredient.  This helps the formulation scientists learn what specific steps 
in the manufacturing process are critical to the performance of the of the oral solid dosage unit.   
The dissolution QC test is also used to study the oral solid dosage performance over time 
at certain temperatures and humidity conditions.  These studies are known as stability studies.4 
The stability study is conducted by putting the drug product in a container, or can be open dish, 
and placed in qualified chambers that maintain a certain temperature and humidity.  An example 
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of a stability study design is shown in Table 1 below.  The dissolution test will be used to 
compare results from the different conditions as well as monitor changes in the release profile in 
each condition over time.  This means the 24-month release profile will be compared to the 
earlier time point release profiles.  These are usually plotted together to better detect any trends 
or changes in the release profiles. 
Table 1: Stability Study Design Example for a Single Lot of Drug Product in 30ct HDPE Bottle 
Condition 0 month 1 Month 3 Month 6 Month 9 Month 12 Month 24 Month 
5 ℃  Test Test Test Test Test  
30 ℃/ 
65% RH Test Test Test Test Test Test Test 
40 ℃/ 
75% RH  Test Test Test    
 
The quality control test is developed to create a strong reproducible dissolution release 
profile for an oral solid dosage unit.  The IVIVC method takes a release profile calculated from 
clinical data and creates a lab dissolution method that will create the same profile.  The reason 
for this is to potentially apply for a biowaiver which can save time and money for the 
pharmaceutical industry.6-9 
The IVIVC test starts with the clinical release profile and works backwards to establish 
the dissolution instrument running parameters, media, etc.  Development in the USP Apparatus 2 
system will focus primarily on varying the paddle speed and the composition of the dissolution 
medium.  Paddle speeds could be dropped below the normal 50 RPM to decrease agitation which 
slows the disintegration rate of the oral solid dosage and there by decrease the release of the 
active pharmaceutical ingredient.   
The IVIVC dissolution media may deviate from the QC test to a media that is more 
physiologically relevant.  These media incorporate the use of salts and enzymes as well as can 
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mimic the fed and fasted stated of a typical adult human.14-18 The media is a fantastic example of 
matching the true physiological model, however, it has a few disadvantages which keep it from 
being used routinely in the QC dissolution test.   
First, the media may have an expiry of a few hours which can impact how the test is 
conducted.  Next, the matrix of the media is much more complex, and the simple UV standalone 
system may not be able to be used due to interference from the media matrix.  Lastly, there are 
new issues that arise for the analytical determination on the HPLC as well.  Media matrix peaks 
may interfere with the active pharmaceutical peak.  The sample solutions may need to be further 
filtered prior to injection on the HPLC.  With each filtration step the repercussions to the active 
pharmaceutical ingredient must be closely monitored and tested. 
Once the IVIVC method is developed and validated it can be used to show 
bioequivalence between different formulations which can eliminate the need for costly clinical 
trials and reduce the time to get the drugs to patients.  This is completed by testing the new 
formulation and the original formulation side by side in three different media using the 
dissolution parameters validated in the IVIVC test.  The release profiles are compared between 
the two formulations and the f2 statistical test is used to show equivalence between the profiles.  
If this is met, again, this would eliminate the need to perform extra costly and time-consuming 
clinical trials allowing the new formulation to get to patients faster. 
In the end, the IVIVC method once developed and validated will, in most cases, be very 
different when compared to the QC method due to the changes in the USP Apparatus system 
operating parameters and the media.7 In this research, there will be a focus to combine these two 
methods into a single test using a completely different system that was developed to better 
illustrate the fluid levels and stresses on the solid oral dosage form as seen In Vivo.  However, to 
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understand this research fully, a basic overview of the human physiological digestive system is 
needed. 
1.3 Human Physiological Digestive Basic Overview 
This section focuses on the parts of the human fasted digestive state relevant to the solid 
oral dose disintegration and dissolution in the stomach and follow the drug as it passes to and 
through the duodenum.  The mouth, intestines and colon will not be covered in this research.  
The focus of this research was centered on immediate release drugs in a fasted human model.  
An immediate release drug for purposes of this research will be defined as a drug that rapidly 
(under 20 minutes) releases the API from the selected oral dosage form in the stomach media.   
The stomach is the organ in the body where most food digestion occurs.19 When in the 
fasted state the stomach is not actively digesting as food is not present in the stomach.  In the 
fasted state the stomach still carries a small volume of gastric media.  The media volume in the 
stomach is not static.  This means that we swallow saliva and the stomach will secrete a small 
amount of stomach juices in the fasted stated which add to the volume of media present in the 
stomach.  As these fluids are added to the stomach, the stomach also passes a small volume of 
the gastric media to the duodenum chamber to maintain a steady state volume.  The fluids in both 
the stomach and the duodenum are complex with salts and enzymes being present in varying 
degrees throughout the digestive cycles.   
 With the brief overview of the human physiological model being used in this research, 
the focus now is on the issues with the current USP Apparatus 2 system to understand how this 




1.4 Problems with the USP Apparatus II System 
Over the years there have been several problems highlighted with the USP dissolution 
apparatus 2 system.  These problems vary from fluid dynamics within the vessel, incorrect 
volumes being used, and that the dissolution test is in a single compartment.  With each of these 
issues noted there have been multiple attempts to solve them and implement changes to the 
dissolution testing.   
1.4.1 Fluid Dynamics of the Dissolution Vessel 
 The dissolution vessel is a one-liter round bottom vessel with typically 900 mL of media 
present.  A paddle is used for mixing the media during the test and it is positioned per the USP 
standards.10 The paddle spins at 50, 75 or 100 rotations per minute (RPM).  See Figure 2 from 
Bing Wang et al for a standard depiction of a USP apparatus II dissolution vessel.20 
 
Figure 2:  USP Apparatus II Dissolution Vessel20 
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 The design of the dissolution vessel is set up so that when a tablet is added to the media it 
sinks to the bottom of the vessel and centers right under the center of the paddle.  The issue with 
this is shown in Figure 3.  This figure depicts that centered directly under the paddle shaft is a 
dead zone for fluid flow or agitation depicted by the blue color.  As there is little to no fluid flow 
the boundary layer is relatively large.  Following the Nernst Bruner equation this will result in a 
smaller dissolution rate that is a result of a design issue with the instrument. 
 
Figure 3:  Fluid Velocity Contours of the USP Dissolution Apparatus II Vessel with Tablet20 
 This phenomena of the dead zone beneath the paddle also plays a major role in achieving 
a complete release profile when the dosage form breaks apart but forms a cone of excipients at 
the bottom of the vessel directly below the paddle.  This is known as coning or mounding.  The 
excipients act as an additional barrier between the drug and the media.  This is an exaggerated 
added artifact for the boundary layer which further degrades the dissolution rate. 
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 An acceptable way to reduce the mounding effect in the industry is to increase the RPMs 
of the paddle.  By increasing to 75 RPM, the dead zone becomes smaller.  Increasing to 100 
RPM will reduce the dead zone further.  Increasing the RPM to 250 will eliminate the dead zone 
all together.  However, the faster the stir rate means the more stress on the tablet in the vessel.  
More stress than what may be seen in a stomach in the fasted state. So now the issue is that the 
dissolution rate may be too fast as the boundary layer is being reduced by the artifacts of the 
instrument. 
 Another option to reduce the issue of the dead zone was the incorporation of a peak 
vessel which can be seen in Picture 2.  The peak vessel has a small mound that is centered under 
the paddle shaft.  This acts as a blocker for the dosage unit, not allowing it to enter the dead 
zone.  The tablet is now in the higher velocity rate of the system as shown in Figure 3.  As 
investigated by Tahseen Mirza et al., the average percent released for high and low solubility 
drugs using the peak vessel increased when compared to the USP Apparatus II dissolution vessel 
and was comparable to the results obtained at a higher rate of paddle rotation of 75 RPM vs the 
original 50 RM of the method.21    
 
  Picture 2: Varian Peak Vessel 
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 S.A. Qureshi developed a novel solution for the dead zone that is known as the Spindle 
Arm.22 The crescent shaped spindle can be seen in Figure 4.  In this instance the spindle arm 
would replace the paddle.  Rotations were decreased as there were increased stresses applied to 
the dosage forms as they were pushed through the media along the bottom of the vessel.  As a 
result, the dissolution rates were higher due to a lower boundary layer that was the result of the 
spindle brush arm.  This manipulation of the tablet stopped further pursuit of this research. 
 
 
Figure 4:  Spindle Arm Research Schematic22 
 While research for improving this instrument flaw was proceeding, Bertil Abrahamsson, 
et. al. devised an experiment to measure the sheer forces on a tablet in a fed stomach.23 In this 
experiment they rigidly suspended a tablet in a cylinder of media.  The cylinder rotated allowing 
the media to pass by the tablet.  A depiction of this experiment can be seen in Figure 5.  This 
research was to understand the shear forces applied to the tablets in media.  But its design could 
not be used for day to day QC testing showing the release of the drug from the tablet as the tablet 
had to be manipulated to be suspended in the fluid.  The manipulation can cause defects of the 
tablet that will allow for quicker dissolution than designed. 
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Figure 5:  Illustration of Rotating beaker with Fixed Tablet23 
 This section sums up the need to look for a different mixing mechanism than the paddle 
due to the issues with the dead zone directly under the paddle.  Also, the sheer forces on the 
tablets are not the same from the paddle mixing design.  Somehow, the research needs to have 
the tablet ‘bounce’ around in the media, like it would in the stomach. 
1.4.2 Media Volume  
 As discussed in 1.3, the actual volume of media in the stomach of a fasted individual who 
has taken one glass of water with the drug is between 260 mL and 340 mL.  The dissolution test 
is typically run with volumes of media between 500 mL and 1000 mL, with the most common 
volume being 900 mL.10  
In the stomach saliva and other excreted fluid is added to the volume while solution is 
passed on to the duodenum. The volume moving to the duodenum is greater than the excreted 
fluid and saliva being added to the contents as the stomach is working to get back to its normal 
35 mL to 50 mL steady state volume.  Meanwhile the duodenum also maintains its 100 mL 
volume.   
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 This research will focus on actual media volumes in the fasted human model.  Higher 
dose drugs only have up to 50 mL to play with for solubility.  A 100mg dose would require a 2 
mg/mL solubility level at least.  What effects happen when the drug is not soluble enough and 
the particles drift through the duodenum undissolved?  This is a question that cannot be 
answered by the current USP apparatus 2 system.   
1.4.3 Multi Compartment Dissolution Systems  
Novel new instruments were being designed to try and mimic the tablets performance in 
the stomach.  One of the better instruments developed to simulate the human digestive system 
(and is being used today) is the TNO Gastro-Intestinal Model (TIM).24 This instrument can be 
seen in Figure 6.  It is a multi-compartment model that can simulate both the FED and FASSIF 
state of the human digestive model.  Each compartment is designed to simulate the proper juices 
for digestion.  Each compartment can be sampled from as needed for the experiment.  And the 
TIM model has a patented transfer process from one compartment to the next that allows solid 
material to pass down the digestive track.  This system can be used to evaluate food effects for 
the new drug entities or test that novel dosage form is releasing as it was designed to do as it hits 




Figure 6:  Schematic Diagram of TNO TIM-1 Model25 
While the TIM-1 system is one of the most physiologically relevant dissolution apparatus 
for use in drug development,5 it is not designed for day to day QC testing.  The TIM-1 system is 
a very complicated, very large instrument.  Setting up the system, performing the test, breaking 
down the instrument and cleaning to prepare for the next test is a full day’s job that provides a 
single tablet result.  A single USP Apparatus 2 system can be run manually in under 2 hours26 
and 2 systems can be run together with a standalone UV analysis finish and being fully 
documented in approximately 6.5 hours.26 Each USP Apparatus II system runs 6 dosage units.  In 
one day, a QC analyst can run 12 tablets with the USP Apparatus II system, or 1 tablet using the 
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TIM instrument.  Through put is a key deliverable for a QC lab and therefore the TIM model 
would not meet this standard. 
 Deanna M. Mudie et. al. created a three-compartment dissolution system.27 It is a clean 
and robust system that can be easily turned over and run again quickly.  Much quicker than the 
TIM model. However, the problem with the three-compartment system was the mixing being 
utilized.  The mixing is completed by a paddle. As shown before the mixing by a paddle creates 
the dead zone space under the paddle where the tablet will feel little to no effects of the fluid 
flowing over the tablet to disintegrate it.  But it also has the wrong sheer force being applied to 
the tablet.  In the stomach, fluid does not flow over the tablet.  The tablet flows through the fluid.  
The stresses on the tablet are different as shown by Bertil Abrahamsson, et. al..23 
 Another multi compartment model developed is known as GOLEM.  As discussed by 
Ivan Stupak et. al., the system was developed to test 4 sections of the digestive tract in line: the 
stomach, the duodenum, the jejunum and the ileum.28 The system uses infusion bags that are 
mixed trough an ‘electrically driven agitation/peristaltic system with autonomous mixing for 
each compartment.’28 It is a unique system that has shown some good data.  The issue with this 
system is focused on the robustness and repeatability.  The experimental data has shown a large 
%RSD for the compartments.  The best two that were chosen in this research had variability of 
25% at the start to under 10% at the finish for the higher agitation rate and 50% at the start of the 
lower agitation rate to a little higher than that of the high agitation rate at the end.  As a 
comparison, USP apparatus 2 systems goals are to be under 6 %RSD after 10 minutes.   
 The following goals have been developed for this research system to stand out from the 
current systems being developed. 
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1. The system will use a mixing mechanism that allows the tablet to flow through the media, 
rather than the media over the tablet. 
2. The system will use volumes of media reflecting the fasted state.  The system will not use 
static volume in a single chamber. 
3. The system is to be reproducible.  %RSD values should be tight, like the USP apparatus 2 
system during method validations. 
4. The system must be focused for QC.  It needs to be able to be cleaned and rerun quickly.  
A single analysis should run the same amount of time as the current USP apparatus 2 
system. 




Chapter 2. Materials and Methods 
2.1 Chemicals and Standards 
Table 2: Chemicals, Samples and Standards Used 
Chemical Manufacturer Purity/Grade 
Deionized (DI) Water Amgen Lab/ Millipore Milli Q  
1 N Hydrochloric Acid (HCl) Fluka 1.0 N 
5 N HCl JT Baker 5.0 N 
Acetonitrile (ACN) Sigma Aldrich HPLC+ (≥ 99.9%) 
pH 4.5 Acetate Dilute 
Solution 
Fluka 
2.99 g/L sodium acetate, 
1.68 g/L acetic acid 
Sodium Acetate Anhydrous Fisher Bioreagents ≥ 99.0% 
Glacial Acetic Acid Sigma Aldrich ≥ 99.7% 
0.01 N HCl Dilute Solution Fluka 0.01 N 
 
2.2 Oral Solid Dosage Information 
 Two different oral solid dosage compounds were used for this research.  One was an 
immediate release tablet formulation and the other was an immediate release capsule 
formulation. 
2.2.1 Tablet Formulation 
 The compound used in the tablet will be referred to as Compound T.  Compound T is 
considered a BCS class 2 drug.  It was formulated into tablets of 1 mg strength using common 
excipients.  The tablet target weight was approximately 100 mg for a 1% drug load.  The pKa 
and solubility of the drug is shown in Table 3. 
Table 3: Compound T pKa and Solubility 
pKa 6.26 
Solubility pH 2.4 33.9 mg/mL 




2.2.2 Capsule Formulation 
The compound used in the capsule will be referred to as Compound C.  Compound C is a 
BCS class 2 drug.  It was formulated into capsules of 1 mg strength using common excipients 
and gelatin capsule shell.  The target capsule fill weight was approximately 100 mg, for a 1% 
drug load as well.  The pKa and the solubility of this drug is shown in Table 4. 
Table 4: Compound C pKa and Solubility 
pKa 5.30, 3.31 
Solubility pH 1 7.7 mg/mL 
Solubility pH 7 < 0.001 mg/mL 
 
2.3 Development of Research Instrumentation  
This research required the development and validation of a new instrument that met the 
following goals.   
1. The system will use a mixing mechanism that allows the tablet to flow through the media, 
rather than the media over the tablet. 
2. The system will use volumes of media reflecting the fasted state.  The system will not use 
static volume in a single chamber. 
3. The system is to be reproducible.  %RSD values should be tight, like the USP apparatus 2 
system during method validations. 
4. The system must be focused for QC.  It needs to be able to be cleaned and rerun quickly.  
A single analysis should run the same amount of time as the current USP apparatus 2 
system. 
5. The system should be able to demonstrate a relationship with Gastro Plus modeling 
where the absorbance in the modeling software would be set to zero as this instrument is 
focused on the dissolution of the active ingredient rather than drug absorbance. 
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The goals are intertwined with one another.  For example, the mixing mechanism could not 
be developed without considering the media volumes being used first. 
2.3.1 Research Instrument Concept 
 The research instrument was designed to be a multi compartment system.  This resolves 
the problem of the current USP dissolution test being static.  It also opens possible new insights 
into the passage of the active pharmaceutical ingredient through the gastric and duodenum 
compartments.  For example, the experiment could track the dissolved active pharmaceutical 
ingredient as it passed from the gastric compartment through the duodenum compartment.   
The research instrument used physiological media volumes present in the human stomach 
and the duodenum while in the fasted state.  This provided a unique challenge in the 
development as the gastric and duodenum volumes in the fasted state are small.  Wickham and 
colleagues recorded the gastric media in the fasted state was approximately 50 mL.29 Mudie et al 
reported 35 +/- 7 mL of media was present in the fasted stomach during their research.27 In the 
fasted state the duodenum media volume can be 33 mL30 per Culen et al or 100 mL31 per 
Takeuchi et al.  For this research the gastric compartment volume would be set at 50 mL and the 
duodenum compartment volume would be 100 mL. 
As medicinal directions state to take the medicine with a glass of water this experiment 
included the volume of one glass of water (240 mL) being introduced at the start of the 
experiment.  The total volume of the gastric compartment at the start of the experiment is 290 
mL.   The system needed to expel the 240 mL of water volume to come back to the resting 
volumes in the gastric (50 mL) and the duodenum (100 mL) compartment by a certain time.   
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The time it takes the stomach to expel 50% of the 240 mL of water to reach the steady 
volume was reported by Mudie et al at 13 minutes.27 By 45 minutes they reported that  the steady 
volume of 35 +/- 7 mL is reached.27 GastroPlus, a modeling software tool used in the 
pharmaceutical industry was also be used in this research. The default software value for 
stomach transit time is 15 minutes.  This 15-minute default value was used to reach steady state 
volumes between the gastric and duodenum compartments in the developed apparatus.  As a 
reminder, the steady state volumes were 50 mL for the gastric compartment and 100 mL for the 
duodenum compartment.   
This created a problem on how the research instrument could be built where fluids were 
transferred in and out of each of these compartments.  The flow rates needed to be adjusted 
during the experiment as well.  The solution was to use a single line peristaltic pump with a 
manual control of the pump speed for each transfer.  The tubing of the pump needed to have a 
large enough diameter to be able to move small chunks of undissolved material from one 
chamber to the next.  This again was to simulate the possibility of what happens in the human 
stomach.           
The volumes of the media used, and the physical presence of the transfer lines were 
considered when developing the mixing mechanism.  The first mixing concept was to create an 
enclosed cylinder compartment that would slowly rotate on the axis.  This would allow the tablet 
to continually fall through the solution.  But the oral solid dosage would contact the hard side of 
the canister and could lead to physical manipulation of the dosage product.  This meant that the 
dosage form would disintegrate faster in the system leading to a faster dissolution rate than what 
would be seen in the GastroPlus modeling.  Other difficulties that arose with this concept was 
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how to keep the canister heated at 37℃, how to sample from the canister, and how to keep the 
transfer lines twisting together as the canister rotated.   
The research by Abrahamsson et al discussed that the tablet jumped in the stomach from 
the contractions.23 This correlated to the reciprocating nature seen in the disintegration 
instrument.  The instrument can be seen in Picture 3.  The instrument uses a reciprocating motion 
that moves six tablets up through media, does not break the surface of the media at the apex, and 
then the unit drops back down allowing the dosage unit with a weighted plastic ‘lid’ on top of it 
to be pushed back to the bottom.  The system handles multiple dosage units at a time in a single 
vessel.  The system uses more than the 50 mL minimum volume needed for this research.  But 
the reciprocating action was promising as it mimicked the Abrahamsson concept quite well. 
 
Picture 3: Disintegration Test Instrument 
 For the reciprocating mixing action design to be used a new system and a smaller sample 
holder had to be chosen.  First, the system needed to hold multiple vessels or compartments that 
were kept at a steady temperature.  The Agilent (Varian) disintegrator unit holds up to six vessels 
in a hot water bath and was chosen for the reciprocating arm and the hot water bath.  The flat 
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bottom 900 mL glass dissolution vessel was used at each location of the system instead of the 
traditional 900 ml beaker vessel for the unit.  Second, the USP apparatus III sample holder with a 
45 µm size mesh bottom was chosen to be suspended by the reciprocating arm.  The arm was set 
to 30 dips per minute with the total travel distance of 18 mm using a chain and stopping 
mechanism.  This ensured the oral solid dosage form did not get lifted above the surface of the 
50 mL volume in the 900 mL flat bottom dissolution vessel.  The mesh screen on the bottom of 
the USP apparatus III holder would allow small particles of undissolved material to pass through 
and be sucked up in the peristaltic tubing to the next compartment. 
 A schematic of the research instrument is shown in Figure 7 below.  All compartments 
depicted in the schematic are suspended in the same hot water bath set to 37 ⁰C.  The research 
instrument and the USP Apparatus III sample holder is shown in Picture 4.  Due to the low 
media volume in each vessel, weights were added to the top to keep the dissolution vessels from 
popping up out of the hot water bath.  
 
Figure 7: Design Schematic of Research Instrument  
 
A – Gastric Reservoir 
B – Gastric Compartment 
C – Duodenum Compartment 
D – Duodenum Reservoir 
E – Waste Compartment 
Circles represent pumps 
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Picture 4: Research Instrument and Apparatus 3 Sample Cell 
2.3.2 Research Instrument Design Refinement 
Once the instrument was built the next step was determining the media to use in each 
compartment, the flow rates between the vessels and creating the sampling plan of the aliquots. 
2.3.2.1 Media Determination 
 One of the goals of this research was to create an instrument that could be used in the 
quality control lab.  To meet this goal the media needed to be easily made and have a long 
expiration date.  While using the biorelevant media available would be a better model for the 
human gastric system, the media is difficult to make, and can have interference issues with 
standalone UV systems.  The expiration date of the biorelevant media can be very short; 
measured in only a couple hours. The traditional dissolution media, 0.01 N HCl and pH 4.5 
acetate buffer, is familiar to the quality control analysts, is easily made, and the expiration of the 
media can be up to a month. Therefore, this media was chosen for this research.      
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 At the start of the experiment the gastric reservoir is filled with 200 mL of the 0.01 N 
HCl and the gastric compartment is filled with 50 mL 0.01 N HCl.  The duodenum reservoir is 
filled with 200 mL of pH 4.5 acetate buffer and the duodenum compartment is filled with 100 
mL pH 4.5 acetate buffer.  
2.3.2.2 Determining Flowrates 
 There were two sets of flowrates to determine for the system.  The first set of flowrates 
allowed the system to maintain the same volumes of 50 mL in the gastric compartment and the 
100 mL in the duodenum compartment.  Takeuchi et al showed the transfer rate used from the 
gastric reserve to the gastric compartment in the laboratory experiment was 1 mL/min.31 In the 
same research the transfer rate from the gastric compartment to the duodenum compartment was 
also 1 mL/min to maintain a steady volume in the gastric compartment.31 The media transfer rate 
from the duodenum reservoir to the duodenum compartment was 1 mL/min.  Because of these 
two additions to the duodenum compartment (1 mL/min from the gastric compartment and 1 
mL/min from the duodenum reservoir) a 2 mL/min rate was used to remove media from the 
duodenum compartment to the waste compartment.   
The second set of flowrates were used to bring the starting volume of the gastric 
compartment down from 290 mL to 50 mL in 15 minutes to match the GastroPlus modeling 
gastric transit time parameter while maintaining the 100 mL volume in the duodenum 
compartment.  The flowrate from the gastric compartment to the duodenum compartment was 
calculated to be 17 mL/min.  With this amount being added to the duodenum compartment along 
with the 1 mL/min from the duodenum reservoir, the exit volume of the duodenum compartment 
was determined to be 18 mL/min to maintain 100 mL volume.  A summary table of these 
flowrates are shown in Table 5. 
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Table 5: Summary of Target Transition Rates 
Pump Description 
Transition Flowrate (mL/min) 
0 Minutes to 15 Minutes 
Transition Flowrate (mL/min) 
15 Minutes to End of Test 
Pump 1 - Gastric Reservoir to 
Gastric Compartment 
1.0 1.0 
Pump 2 – Gastric 
Compartment to Duodenum 
Compartment 
17.0 1.0 
Pump 3 – Duodenum 
Reservoir to Duodenum 
Compartment 
1.0 1.0 
Pump 4 – Duodenum 




Samples were pulled from the gastric compartment and the duodenum compartment at 5, 
10, 15, 20, 30, 45, and 60-minute intervals.  Samples were pulled through a 45 µm filter tip filter 
fitted on a stainless steel canula attached to a 5 mL syringe.  5 mL’s were collected into marked 
test tubes at each time point.  5 mL’s of the relative media was then reintroduced to the 
appropriate compartment following each time point to maintain steady volumes.  The duodenum 
5 mL sample aliquots were filtered through a 5 µm filter tip filter and collected into an 
appropriately marked secondary test tube.  All test tubes were covered with parafilm after each 
collection to minimize sample loss.  Samples were analyzed by the appropriate analytical 
technique, either standalone UV or HPLC. 
2.3.3 Experimental Refinement 
 With the initial parameters in place a series of experiments were set up to test the 
instrument and further refine the operating parameters.  Questions were quickly answered as 
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well.  For example, how would a capsule fare in this instrument since a capsule could float on the 
surface of the media in the sample cell?  Would the capsule take longer to disintegrate than the 
traditional USP apparatus II test where the capsule is completely submerged?  The research 
experiment showed that the part of the capsule exposed to the media did disintegrate quickly and 
the contents fell through the solution as it settled to the bottom of the vessel.  Further, solid 
particles were observed being transferred to the duodenum and the waste compartments. 
A few key lessons learned through the experimental refinement of the operating 
parameters of the instrument included optimizing the media in the duodenum compartment, 
improving the positions of the transfer lines, and refining the sampling timepoints. 
2.3.3.1 Optimizing the Duodenum Media 
The first experiment demonstrated that the media in the duodenum compartment was 
incorrect.  The duodenum fluid is targeted be pH 4.5 acetate buffer.  The emphasis was on the 
pH of the media.  And while 100 mL of pH 4.5 acetate buffer was used to start the experiment, 
the1:1 mixture of the 0.01 N HCl media with pH 4.5 acetate buffer media being added to the 
compartment was not considered to maintain the pH.  At the end of the experiment the pH was 
measured at 3.6 for the duodenum compartment. 
Bench top experimentation was conducted to find the correct mixture to yield a final pH 
of 4.5.  This was accomplished by mixing different pH level USP sodium acetate solutions with 
0.01 N HCl on a 1:1 ratio in a hot water bath at 37 ℃.  The correct 1:1 mixture contained a pH 
5.0 acetate buffer mixed with 0.01 N HCl. 
All subsequent experiments were corrected for this error.  The starting 100 mL solution 
in the duodenum compartment was comprised of 50 mL of 0.01 N HCl and 50 mL of pH 5.0 
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acetate buffer.  The duodenum reservoir was comprised of 200 mL of the pH 5.0 acetate buffer 
media.  Standards made for the duodenum compartment analysis were dissolved in and diluted to 
volume with the 1:1 mixture of 0.01N HCl and the pH 5.0 acetate buffer.  
 2.3.3.2 Improving the Position of the Transfer Lines 
 The placement of the transfer lines was another important consideration discovered 
during the early experimentation.  At first the lines were positioned so that they were all 
submerged.  Depth of the transfer lines was not a focal point and the lines were not in a fixed 
position.   
Results of the experiments were variable in the beginning and one main factor was the 
transfer lines.  First, with the transfer lines loose and not fixed, more than once a line would be 
removed accidently during the sample pulls where the lid of the vessel or the sample cannula 
would move the transfer line out of the media.  Second, if the lines were submerged to the 
bottom of the vessel, they tended to pull in the larger undissolved excipients which would block 
the transfer line.   
Through trial and error, the best practice for the transfer lines was determined.  The lines 
removing fluid were positioned just slightly off the bottom of the flat bottom vessel.  They were 
taped into position.  The transfer lines that delivered the volume to a vessel were fixed so the 
media would drip into the vessel.  This allowed easier visual confirmation that the lines were not 
blocked by excipients during the experiment. 
2.3.3.3 Improving Sample Timepoints 
 In the beginning of the experimentation the timepoints used were carried over from the 
traditional USP dissolution testing methodology.  The samples were pulled at 5, 10, 15, 20, 25, 
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30, 45 and 60 minutes.  However, in comparing the models generated from GastroPlus to the 
results delivered from the research instrument, it was determined that more timepoints earlier 
were needed.  This was to better capture the max amount of drug present in the gastric 
compartment.  The new sample timepoints were 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 45 and 60 
minutes. 
2.4 Calculations 
 Calculations were created to mathematically determine the volumes of the gastric and the 
duodenum compartments for the three stages of the experiment.  The first stage of the 
experiment is where the high transfer rates expel the extra 240 mL of water present in the 
system.  The second stage of the experiment is the transfer rates change from high to low 
between two sample pulls.  The third stage is the transfer rates are low and set to maintain a 
constant volume in each compartment.   
 It is important to note that targeted rates are theoretical.  Since the transfer rates are 
calibrated using peristaltic pumps with different tubing, the transfer rates in and transfer rates out 
for compartments will not be equal.  These equations will be able to calculate the actual volume 
at any time of the experiment when using the calibrated transfer rates calculated prior to the 
experimental run. 
2.4.1 Gastric Compartment Calculations 
 The gastric compartment starts with 240 mL DI water and 50 mL 0.01 N HCl for a total 
start volume of 290 mL.  This volume is reduced over 15 minutes to 50 mL.  The volume is 
targeted to remain constant for the remainder of the experiment at 50 mL.  Sample time points 
are 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 45 and 60 minutes. 
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2.4.1.1 First Stage of Experiment 
VolumeT = 290 + (TRI * T) – (HTRO * T)   Equation 1 
 Equation 1 is used to determine the variable volume of the gastric compartment during 
the first stage of the experiment.  VolumeT is the volume in the gastric compartment at sample 
time point (T).  290 mL is the starting volume of the gastric compartment.  TRI stands for the 
transfer rate into the gastric compartment.  HTRO stands for the high transfer rate out of the 
gastric compartment.   
 An example of this equation is shown below where the volume at 10 minutes is 
determined with a transfer rate into the gastric compartment is 1 mL/min and the transfer rate out 
of the compartment is 17 mL/min.   
290 + (1 * 10) – (17 * 10) = 130 
2.4.1.2 Second Stage of Experiment  
VolumeTT = 290 + (TRI * TA) – (HTRO * TT) – (LTRO * (TA – TT))  Equation 2 
 Equation 2 is used to determine the volume in the gastric compartment when the transfer 
rates change from high to low between two sample collection time points.  290 was the starting 
volume of the test.  TA is the sample time point after the transfer rates change from high to low.  
TRI is the transfer rate into the gastric compartment.  HTRO is the high transfer rate out of the 
gastric compartment.  TT is the actual transition time from high transfer rate to low transfer rate.  
LTRO is the low transfer rate out of the gastric compartment.     
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 An example of this equation to determine the volume at 20 minutes is shown below 
where the high transfer rate out is 17 mL/min, the low transfer rate out is 1 mL/min, and the 
transition time is 15 minutes.   
290 + (1 * 20) – (17 * 15) – (1 * (20 – 15)) = 50 
2.4.1.3 Third Stage of Experiment 
 VolumeT = VolumePT + (TRI * (T – PT)) – (LTRO * (T – PT))  Equation 3 
 Equation 3 determines the volume in the gastric compartment when the transfer rate out 
of the compartment is low for the remainder of the experiment.  VolumeT is the volume in the 
gastric compartment at the current sample time point.  The volume of the gastric compartment at 
the previous time point is denoted as VolumePT.  TRI is the transfer rate in.  LTRO is the low 
transfer rate out.  PT is the time of the previous time point. 
 An example of this equation to determine the volume at 30 minutes is shown below.  The 
transfer rate in and the transfer rate out are both 1 mL/min.   The volume at 25 minutes (the 
previous time point) is 50 mL. 
50 + (1 * (30-25)) – (1 * (30-25)) = 50 
2.4.2 Duodenum Compartment Calculations 
 The duodenum compartment starts with a volume of 100 mL.  The volume is to remain 
steady throughout the experiment.  This is made difficult as there are two lines adding media to 
the compartment while one removes the media.  The transfer line from the gastric compartment 
to the duodenum compartment and the transfer line from the duodenum compartment to the 
waste compartment will change during the experiment. 
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2.4.2.1 First Stage of Experiment 
VolumeT = 100 + (DRTRI * T) + (GCHTRI * T) – (HDCTRO * T)             Equation 4 
 Equation 4 is used to determine the volume in the duodenum compartment when the 
transfer rate from the gastric compartment and the transfer rate to the waste compartment is high.  
VolumeT is the volume in the duodenum compartment at the current sample time point.  DRTRI 
is the duodenum reservoir transfer rate in.  GCHTRO is the gastric compartment high transfer 
rate in.  HDCTRO is the high duodenum compartment transfer rate out of the duodenum 
compartment.     
 An example of this equation to determine the volume in the duodenum compartment at 
10 minutes is shown below.  At this point the transfer rate in from the gastric compartment is 17 
mL/min and from the duodenum reservoir is 1 mL/min.  The transfer rate out of the duodenum 
compartment is 18 mL/min.  
100 + (1 * 10) + (17 * 10) – (18 * 10) = 100  
2.4.2.2 Second Stage of Experiment  
VolumeTA = 100 + (DRTRI * TA) + (GCHTRI * TT) + (GCLTRI * (TA – TT))  
– (DCHTRO * TT) – (DCLTRO * (TA – TT))  Equation 5 
 
 Equation 5 was used to determine the volume (VolumeTA) in the duodenum compartment 
at the sample time point after the transition rates switch from high rates to low rates.  100 mL 
was the starting volume in the duodenum compartment.  TA is the sample time after the 
transition to slower rates.  DRTRI is the duodenum reservoir transfer rate into the duodenum 
compartment.  GCHTRI is the gastric compartment high transfer rate into the duodenum 
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compartment.  GCLTRI is the gastric compartment low transfer rate into the duodenum 
compartment.  DCHTRO is the duodenum compartment high transfer rate out of the duodenum 
compartment.  DCLTRO is the duodenum compartment low transfer rate out of the duodenum 
compartment.  TT is the calculated transition time for switching the transition rates from high to 
low.     
 An example of this equation to determine the volume in the duodenum compartment at 
20 minutes (TA) is shown below.  The transition time from high rates to low rates was 15 
minutes.  The high transfer rate into the duodenum compartment from the gastric compartment 
was 17 mL/min and from the duodenum reservoir was 1 mL/min.  The high transfer rate out of 
the duodenum compartment was 18 mL/min.  The low transfer rates into the duodenum 
compartment was 1 mL/min for both the gastric compartment transfer line and the duodenum 
reservoir line.  The low transfer rate out of the duodenum compartment was 2 mL/min.   
100 + (1 * 20) + (17 * 15) + (1 * (20-15)) – (18 * 15) – (2 * (20 – 15)) = 100 
2.4.2.3 Third Stage of Experiment 
VolumeT = VolumePT + (DRTRI * (T – PT)) + (GCLTRI * (T - PT)) 
    – (DCLTRO * (T – PT))  Equation 6 
 Equation 6 was used to determine the volume (VolumeT) in the duodenum compartment 
when all transition rates were low for the remainder of the experiment.  The volume of the 
duodenum compartment at the previous time point is VolumePT.  DRTRI is the duodenum 
reservoir transfer rate into the duodenum compartment.  GCLTRI is the gastric compartment low 
transfer rate into the duodenum compartment.  DCLTRO is the duodenum compartment low 
transfer rate out of the duodenum compartment.  PT is the time of the previous time point. 
33 
 An example to determine the volume in the duodenum compartment at 30 minutes (T) is 
shown below.  The previous time point is 25 minutes.  The two transfer rates into the duodenum 
compartment are both 1 mL/min.  The transfer rate out of the duodenum compartment is 2 
mL/min. 
100 + (1 * (30-25)) + (1 * (30 – 25)) – (2 * (30 – 25)) = 100 
2.5 Summary of Research Instrument Running Parameters 
 The following tables outline the research instruments targeted running parameters based 
on the instrument development studies.  Each compound was qualified in each media for 
linearity, accuracy and sample precision (including filter studies). 




bottom of holder) 
Max Depth Max Height Reciprocations per Minute 
2 mm  17 mm  30 
Bath Temperature 37.0 ℃ +/- 5 ℃ Time to Switch transfer rates 15 minutes 
Water volume added at start of experiment to simulate glass of water 240 mL 
 
Table 7: Targeted Sampling Time Points 
Theoretical Pull Time 
(minutes) Gastric Actual Pull Time Duodenum Actual Pull Time 
1 1:00 
N/A 2 2:00 3 3:00 
4 4:00 
5 5:00 5:30 
10 10:00 10:30 
15 15:00 15:30 
20 20:00 20:30 
25 25:00 25:30 
30 30:00 30:30 
60 60.00 60:30 
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Table 8: Targeted Compartment Volumes  




2.6 USP Instrumentation and Methodology 
 Both compounds T and C were tested in their validated USP apparatus II dissolution 
quality control methodologies to establish a baseline data set of which this research instrument is 
compared against.  The n=6 results of this test are reported against a Q value per the USP.  The Q 
value is a statistical result that states the test batch meets the percent amount released.  There are 
three levels to the USP results meeting the established Q value.  They are as follows.  If the 
criteria at the first level is not met, more samples are tested and compared to acceptance criteria 
in the second level.  If the second level acceptance criteria are not met than more samples are 
tested against the acceptance criteria at the third level. 
1. Test six (n=6) samples of the test batch.  All individual samples must meet Q + 5%.  
For example, if Q was set to be 75% at 45 minutes, each individual result must be at 
80% or higher at 45 minutes.  
2. Test a total of twelve (n=12) samples.  The mean result of the twelve samples must 
equal the Q value and not more than 1 sample can be less than Q-15%.  For example, 
twelve samples were tested.  The mean result equaled 75% at 45 minutes.  Only one 
result was below 60%. 
3. Test a total of twenty-four (n=24) samples.  The mean result of the twenty-four 
samples must be equal to or greater than the Q value, not more than two samples can 
be less than Q-15%, and not more than one sample can be less than Q-25%.  For 
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example, at 45 minutes the average of the twenty-four samples was 75% with one 
sample at 59% and another sample at 49%.  All other samples were higher than 60%. 
The following sections outline the equipment and methodology used for Compound T 
and Compound C using current pharmaceutical industry standards. 
2.6.1 Compound T 
 Compound T was validated to be tested on the USP apparatus 2 dissolution instrument 
followed by analysis on a UV spectrophotometer unit. 
2.6.1.1 Instrumentation  
 The dissolution test was performed using the Distek Evolution 6300 bath in the apparatus 
II configuration.  Samples were drawn from the vessel using Chemstation Software for multi-
bath dissolution testing at set intervals and analyzed on an Agilent 8453 UV-Vis calibrated 
system.   
 Balances used during the testing were the Mettler Toledo MT5 for standard preparations 
and the Mettler Toledo AG 245 for the sample weights. 
2.6.1.2 Methodology 
 Compound T was tested on a USP apparatus II dissolution bath.  The media used was 
0.01 N HCl.  Each vessel contained 500 mL of media heated to 37.0 ⁰C ± 0.5 ⁰C.  Temperatures 
were recorded at the start and end of the dissolution test.  Paddle heights were measured at 25.0 
to 25.5 mm from the bottom of the paddle to the bottom of the dissolution vessel.  Paddle speed 
was set to 75 rpm.  Filters used for sample collection were 10 µm full flow filters.  Samples were 
collected at 10, 15, 30, 45 and 60 minutes.  After 60 minutes the rpms were increased to 250 and 
an infinity pull was made at 75 minutes (15 minutes beyond the 60-minute sample pull). 
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 The samples were analyzed using Chemstation UV Multi Bath Software.  Flow cell size 
was 1 cm (10mm).  Wavelength was 240 nm.  There was no background correction.  System was 
suitably blanked prior to analysis using the 0.01 N HCl dissolution medium. 
 Standards were prepared by weighing approximately 8.5 mg of the reference standard 
and transferring to a 250 mL volumetric flask.  The standard was dissolved in and diluted to 
volume with the 0.01 N dissolution media and mixed well.  8.0 mL of this standard was pipetted 
into a 100 mL volumetric flask and diluted to mark with the dissolution media.  The solution was 
mixed well.  This was analyzed on the UV-Vis system prior to the actual run.  A check standard 
was prepared in the same fashion.  System suitability was met prior to analysis of samples. 
2.6.2 Compound C 
 Compound C was validated to be tested on the USP apparatus II dissolution instrument 
followed by analysis on a HPLC instrument. 
2.6.2.1 Instrumentation  
 The dissolution test was performed using the Distek Evolution 6300 bath in the apparatus 
II configuration.  Samples were drawn from the vessels and analyzed on an Agilent 1100 HPLC 
system using Empower 3 software.   
 Balances used during the testing were the Mettler Toledo MT5 for standard preparations 
and the Mettler Toledo AG 245 for the sample weights. 
2.6.2.2 Methodology 
 Compound C was tested on a USP apparatus II dissolution bath with the use of a 
Japanese basket sinker (see Figure 3) for each capsule.  The media used was 0.01 N HCl.  Each 
vessel contained 500 mL of media heated to 37.0 ⁰C ± 0.5 ⁰C.  Temperatures were recorded at 
the start and end of the dissolution test.  Paddle heights were measured at 25.0 to 25.5 mm from 
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the bottom of the basket to the bottom of the dissolution vessel.  Paddle speed was set to 75 rpm.  
Filters used for sample collection were 10 µm full flow filters.  Samples were collected at 10, 20, 
30, 45 and 60 minutes.  After 60 minutes the rpms were increased to 250 and an infinity pull was 
made at 90 minutes (30 minutes beyond the 60-minute sample pull).  All samples were 1 mL 
aliquots. 
 The samples were analyzed on an Agilent 1100 HPLC system using Empower 3 
software.  Mobile phase was acetonitrile/DI water (30/70, v/v) with 0.1% trifluoroacetic acid.  
Flow rate was 1.0 mL/min.  Column used was a YMC Hydrosphere C18 3 µm, 4.6 by 50 mm 
column.  Column temperature was ambient.  Injection volume was 100 µL.  Wavelength 
detection was 325 nm.  System reached a stable baseline prior to the start of the injection 
sequence.  System suitably requirements using blanks, standards and check standards were met 
prior to collection of samples.  Bracketing standards were implemented and confirmed to pass 
suitability as well for all runs. 
 Standards were prepared by weighing approximately 11.0 mg of the reference standard 
and transferring to a 250 mL volumetric flask.  The standard was dissolved in 200 mL 
acetonitrile/DI water (20/80, v/v) with 0.1% trifluoroacetic acid (diluent) with the aid of 
sonication for 5 minutes.  The standard was diluted to volume with diluent and mixed well.  4.0 
mL of this standard was pipetted into a 50 mL volumetric flask and diluted to mark with diluent.  




Chapter 3.  Results and Discussion 
3.1 USP Based Dissolution Results 
 Both Compound T and Compound C were investigational drugs being looked at to help 
patients.  The USP based dissolution methods for both compounds were validated.  Validation 
work included specificity, linearity, accuracy, method precision, sample precision and solution 
stability.  Filter studies were conducted during development of the methods. 
3.1.1 Compound T USP Apparatus II Dissolution Results 
 Compound T is an immediate release 1 mg tablet formulation.  The results of the 
validated USP dissolution test are shown in Table 9 and Figure 8 below.   
Table 9: Compound T (Tablet) USP Percent Released Dissolution Results 
Vessel # 
Time (Minutes) 
10 15 30 45 60 75 
1 90 89 92 92 93 92 
2 91 92 94 95 95 94 
3 93 94 94 94 94 94 
4 93 92 92 92 92 92 
5 94 97 95 95 95 94 
6 95 95 95 95 95 95 
Min 90 89 92 92 92 92 
Max 95 97 95 95 95 95 
Mean 93 93 94 94 94 93 
Std Dev 1.7 2.7 1.4 1.4 1.2 1.4 





Figure 8: Compound T (Tablet) USP Release Profile  
The dissolution specification set for this compound was Q = 75% at 45 minutes.  The lab 
would conclude all results met USP L1 testing criteria where Q + 5 = 80% at 45 minutes for each 
individual unit.  The profile would be compared to other accepted release profiles, if possible, to 
see batch to batch variability or previous dissolution profiles on stability to monitor any changes 
over time. 
The data shows that by 10 minutes the active pharmaceutical ingredient (API) was fully 
released for this experiment.  While the result did not meet 100% release, this could be explained 
by the low dosage of the tablet itself in the formulation.  The tablet had a one percent drug load.  
1mg of the active pharmaceutical ingredient mixed with 99% excipients.  This high blend could 
lead to lower assay recoveries.  Furthermore, all six dosage units have similar profiles as evident 
























Compound T Release Profile
USP AP II, 75 RPM, 500mL 0.01 N HCl
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3.1.2 Compound C USP Apparatus II Dissolution Results 
Compound C is a 1 mg gelatin capsule formulation.  The results of the validated USP 
dissolution test are shown in Table 10 and Figure 9.   
Table 10: Compound C (Capsule) USP Percent Released Dissolution Results 
Vessel # 
Time (Minutes) 
10 20 30 45 60 90 
1 95 100 98 98 101 98 
2 90 94 95 98 97 98 
3 95 97 96 98 97 96 
4 98 102 99 96 98 100 
5 95 97 101 99 98 97 
6 95 96 99 98 100 97 
Min 90 94 95 96 97 96 
Max 98 102 101 99 101 100 
Mean 95 98 98 98 99 98 
Std Dev 2.4 2.8 1.9 1.0 1.6 1.2 
%RSD 2.6 2.9 1.9 1.0 1.7 1.2 
 
 






















Compound C Release Profile
USP AP II, 75 RPM, 500mL 0.01 N HCl
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The dissolution specification for this compound was Q = 75% at 45 minutes.  The lab 
would report the results as ‘all results met USP L1 testing criteria where Q + 5 = 80% at 45 
minutes for each individual unit.’  The profile would be compared to other accepted release 
profiles, if possible, to see batch-to-batch variability or previous dissolution profiles on stability 
to monitor any changes over time. 
The results show that by 10 minutes the API is almost completely in solution.  All six 
dosage units have similar profiles as evident from the low %RSD values in Table 10. 
3.2 GastroPlus Modeling Profiles 
 A GastroPlus software simulation was run for Compound T.  The absorption was set to 
zero, the elimination was 0.25 hours, 50 mL was used for the gastric and duodenum 
compartment volumes, 240 mL volume was used for the glass of water and a one-minute delay 
was added to simulate the time for the tablet to disintegrate.  Profiles of the simulated drug 
amount remaining in mg vs time were plotted for each compartment with data points chosen to 




Figure 10: Compound T GastroPlus Gastric Model Simulation 
 
Figure 11: Compound T GastroPlus Duodenum Compartment Simulation 
 The gastric simulation profile shows the drug is immediately available upon the 
































































Compound T GastroPlus Simulation
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instrument test, at 45 minutes there is less than 10% of the drug present in the gastric 
compartment.  At 60 minutes, less than 2% of the drug is still present in the gastric compartment 
as seen in Figure 10.   
The duodenum simulation profile shows the amount of drug recovered increases up to 
almost 0.4 mg by 15 minutes and then begins to decrease steadily for the next 45 minutes.  This 
profile shows a hold up in this compartment.  Part of this reason is that the absorption was set to 
zero.  Drug would be removed from the fluid as it is being absorbed into the bloodstream.  Per 
the qualification the drug is fully soluble in this media at the 1mg dosage, so solubility is not a 
problem.   
The 2-, 45- and 60-minutes time points provide the most intriguing information when 
compared to the original USP apparatus II test.  The 2-minute time point shows that the drug is 
fully in solution in the gastric compartment and has already begun to move into the duodenum 
compartment.  The USP test showed the drug was completely in solution by 10 minutes and 
stayed completely in solution for the rest of the test. 
The 45-minute time point is where the original USP apparatus II dissolution test 
specification is set.  The specification is Q = 75% at 45-minutes.  Per the GastroPlus simulation 
profiles, there is less than 0.1 mg (less than 10%) of the drug present in the gastric compartment 
and just under 0.2 mg (20%) present in the duodenum compartment at 45-minutes. 
This result highlights one of the main reasons for the need of a new dissolution 
instrument.  By 45-minutes the GastroPlus simulation shows most of the drug left the gastric 
compartment as well as passed through the duodenum compartment.  The USP test is unable to 
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depict this change over time as it is focused on the dissolution rate in a single vessel, whereas 
this research instrument can capture this change over time as it is a multi-compartment system. 
At 60 minutes the drug present is present in both the gastric and duodenum simulations.  
The gastric simulation has less than 2% remaining, where the duodenum has about 8% 
remaining.  This falls in line with the fact that 100% of solution is never fully emptied from the 
gastric compartment.  A fraction of the solution is being constantly transferred (about 2% per 
minute) to the duodenum following second order kinetics.    
3.3 Compound T Research Instrument Results 
3.3.1 Compound T 100 mL Duodenum Volume 
Compound T was optimized on the research instrument per the parameters listed in 
Chapter 2.  The differences were that the duodenum compartment had 100 mL starting volume, 
the flow rate leaving the duodenum compartment was less than the targeted 2.0 mL/min transfer 
rate which allowed for a hold up effect in the duodenum with and ending volume greater than 
100 mL, and the first sample was pulled at 5 minutes.  As a result, the highest spike of the drug 




Figure 12: Gastric Compartment Results for Compound T – 100 mL Duodenum Volume 
 
Figure 13: Duodenum Compartment Results for Compound T – 100 mL Duodenum Volume 
 The tablet was observed to fully disintegrate by 5 minutes.  The tablet formed a mound of 
excipients after the tablet disintegrated as per previous experiments.  The mound of excipients 


















































Compound T - 100 mL Duodenum Volume
46 
 
mound expanded into rings of powder around the center of the flat bottom vessel.  This result 
demonstrates the instruments ability to negate the phenomena known as mounding or coning in 
the dissolution apparatus 2 bath through the reciprocation mechanism of mixing.   
The tablet disintegration observation was backed by the data seen in Figure 12.  The plot 
had the highest mg recovered at 5 minutes.  After, there was a rapid decline of the amount of 
drug recovered during the high flow rate stage of the test.  When the system switched over to the 
slower flow rates the loss of the drug in the gastric compartment flattened out.  There was still 
7% of the drug present in the gastric compartment at 60 minutes. 
 The duodenum compartment result showed that the highest mg recovered of Compound 
T was at the 15 minutes and 30 seconds pull with 41% mg recovered.  This was significantly 
different to previous experimental runs.  Switching the flow rate out of the duodenum 
compartment to be lower than what was coming into the compartment created a hold up of the 
material in the duodenum compartment.  The duodenum compartment also showed that the drug 
was still present at 60 minutes at a level double of what was seen in the gastric compartment.   
It is important to recall that this experiment does not factor in absorption.  This is a QC 
test to see how fast the formulation releases the drug and how fast the drug moves to the 
duodenum compartment.  With absorption included the amount recovered in the duodenum 
would be lower as the drug would be absorbed in the duodenum in addition to the transition to 
the next compartment.  This experiment shows that the greatest amount of the drug is available 





3.3.2 Compound T 50 mL Duodenum Volume 
The research instrument was run per the parameters in chapter 2.  The single difference in 
this experiment was the volume in the duodenum compartment was set to 50 mL.  This was to 
match the volume used in GastroPlus.  Further the results were compared directly to the 
GastroPlus simulation model in section 3.2. 
Using the calculations discussed in chapter 2.4, the amount of drug recovered for each 
compartment at each time point was calculated and populated in Table 11.  The final volume in 
each compartment was used to ensure the volumes were accurate for each sample calculation.   
Table 11: Drug Recovery Results for Compound T – 50 mL Duodenum Volume 
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
1 0.7669 
N/A 2 0.7854 3 0.7822 
4 0.7814 
5 0.7001 5.5 0.1372 
10 0.3936 10.5 0.1399 
15 0.1460 15.5 0.1245 
20 0.1128 20.5 0.0979 
25 0.1033 25.5 0.0780 
30 0.0839 30.5 0.0674 





Figure 14: Gastric Compartment Results for Compound T – 50 mL Duodenum Volume 
  
Figure 15: Duodenum Compartment Results for Compound T – 50 mL Duodenum Volume 
 The gastric data from the research instrument showed the amount of drug recovered in 

























































the same spike level as the GastroPlus simulation had predicted.  This was because the tablet 
does not instantaneously disintegrate releasing all drug at once.  The drug is released as the tablet 
disintegrates and as the first amount of the drug is in solution it is moved quickly to the 
duodenum compartment.  It goes to reason the same occurrence would happen in the human 
digestive tract as well.  This demonstrates how this instrument is different from GastroPlus in 
that the instrument can show the importance in the formulation disintegration as it relates to the 
drug being in solution. 
 The duodenum compartment data did not have a similar profile to the GastroPlus 
simulation.  The highest the experimental data was able to recover was about 14% at 10.5 
minutes.  One reason for this difference was the fact that even though zero absorption was used 
for the drug, the GastroPlus simulation accounted for absorption of the fluid.  After discussing 
this internally, there was a decision to increase the volume of the duodenum compartment to 
offset this absorption factor embedded in the software. 
3.3.3 Compound T 150 mL Duodenum Volume 
 This experiment followed the parameters as outlined in chapter two with the initial 
volume of the duodenum compartment at 150 mL.  The tablet was observed to fully disintegrate 
by 2 minutes.   
 The amount of drug recovered for each compartment at each time point was calculated 
and populated in Table 12.  The final volume was used to ensure the volumes were accurate for 
each sample calculation.  The plots of the two compartments compared to the GastroPlus 




Table 12: Drug Recovery Results for Compound T – 150 mL Duodenum Volume 
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
2 0.8796 
N/A 3.17 0.7311 4 0.6685 
5 0.5827 
6 0.5293 6.5 0.3250 
11 0.2892 11.5 0.3121 
16 0.1143 16.5 0.3014 
21 0.0876 21.5 0.2784 
26 0.0680 26.5 0.2462 
31 0.0512 31.5 0.2288 
61 0.0193 61 0.1703 
 
 































Figure 17: Duodenum Compartment Results for Compound T – 150 mL Duodenum Volume 
The data from the research instrument showed similar profiles in the gastric compartment 
and the duodenum compartment when compared to the GastroPlus model.  The use of the 150 
mL starting volume in the duodenum compartment had held up the amount of drug in solution in 
the duodenum compartment.  In previous experiments, it was difficult to get above 20% as the 
drug was moving out of the compartment so quickly with the lower starting volumes. 
 The research instrument parameters used for this experiment were repeated two more 
times for a total of n=3 reproducibility trial of the instrument and discussed in section 3.3.4. 
3.3.4 Compound T – 150 mL Duodenum Volume, Reproducibility  
Reproducibility of the research instrument was tested by running two more experiments, 
for a total of 3 experiment runs, using the parameters in Chapter 2.  The experimental runs were 






























 The amount of drug recovered for each compartment at each time point was calculated 
utilizing the equations in chapter 2.4 and populated in Tables 13 and 14.  The final volume was 
used in all experiments to ensure the volumes were accurate for each sample calculation.  The 
average plots of all three 150 mL duodenum starting volume experiments were compared to the 
GastroPlus simulation as seen in Figures 18 and 19.  
Table 13: Compound T –150 mL Duodenum Volume, Run 2 
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
1 0.8950 
N/A 2 0.7927 3 0.7360 
4 0.6598 
5.00 0.5939 5.50 0.2285 
10.00 0.3836 10.50 0.1889 
15.17 0.1556 15.50 0.2025 
20.00 0.1156 20.50 0.1989 
25.00 0.0839 25.50 0.1671 
30.00 0.0567 30.50 0.1430 
60.00 0.0090 60.50 0.1142 
 
Table 14: Compound T –150 mL Duodenum Volume, Run 3 
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
1 0.7471 
N/A 2 0.7791 3 0.7508 
4 0.6737 
5.00 0.6356 5.50 0.0711 
10.00 0.4169 10.50 0.1396 
15.17 0.1674 15.50 0.1846 
20.00 0.1250 20.50 0.1683 
25.00 0.0881 25.50 0.1551 
30.00 0.0613 30.50 0.1387 





Figure 18: Gastric Compartment Results for Compound T –150 mL Duodenum Volume, 
Reproducibility (N=3) 
 
Figure 19: Duodenum Compartment Results for Compound T –150 mL Duodenum Volume, 
Reproducibility (N=3) 
 Figure 18 depicts the tight results in the research instrument for the gastric compartment.  

























































the GastroPlus simulation.  The research instrument plot demonstrated a faster evacuation of the 
drug from the compartment than GastroPlus prediction model.     
 The duodenum compartment results were not as tight as the gastric compartment results.  
Both plots have error bars signifying one standard deviation.  Experiment one was completed 
with the instrument being dismantled after its completion.  The research instrument was 
reassembled and kept in the same configuration for experiments two and three.  Experiments two 
and three were run on different days.   
The first experiment showed a good comparison to the GastroPlus simulation.  The 
second and the third experiments showed lower amount recoveries in the duodenum 
compartment.  The final volumes showed there were greater hold ups in experiment two and 
three compared to experiment one.  This should have had experimental runs two and three see 
higher amounts recovered as seen in the experiment with 100 mL duodenum volume.  This was 
due to the theory that more solution with drug was entering the duodenum compartment than 
solution with drug leaving the compartment.  But this was not the case.  The analytical data 
showed material moved quickly through the second compartment into the waste compartment. 
 However, the results did show a good correlation to the overall GastroPlus prediction 
model and therefore these parameters as outlined in Chapter 2 were used for Compound C to see 
the correlation to the GastroPlus model. 
3.4 Comparison of Compound C to GastroPlus  
 Compound C experiment run was conducted using the parameters outlined in Chapter 2.  
The end volumes were used for all calculations to ensure accurate volumes were used for the 
equations.   
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The capsule was observed to float on top of the gastric media.  The capsule ruptured at 
approximately 1 minute and 30 seconds into the experimental run.  The capsule remained 
floating while powder slowly escaped through the rupture on the bottom of the capsule.  It was 
observed that powder continued to fall out of the capsule over the course of the next 5 minutes.  
The pumps were observed to have functioned properly throughout the run without any visible 
line blockage from the particles.   
 Using the calculations discussed in chapter 2.4, the amount of drug recovered for each 
compartment at each time point was calculated and populated in Table 15.  The plots of the two 
compartments were overlaid with the GastroPlus simulation prediction for Compound C and are 
seen in Figures 20 and 21.  
Table 15: Drug Recovery Results for Compound C  
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
1 0.0623 
N/A 2 0.0496 3 0.1685 
4 0.3634 
5.00 0.4686 5.50 0.0590 
10.00 0.3970 10.50 0.3058 
15.17 0.1413 15.50 0.5133 
20.00 0.1143 20.50 0.3781 
25.00 0.0858 25.50 0.3372 
30.00 0.0685 30.50 0.3029 





Figure 20: Gastric Compartment Results for Comparison of Compound C GastroPlus  
 
Figure 21: Duodenum Compartment Results for Comparison of Compound C GastroPlus 
 The research instrument plot for Compound C in the gastric compartment was 
significantly different than the GastroPlus simulation data.  The reason was that the GastroPlus 
simulation assumed 100% of the drug was available in the gastric compartment at the start of the 
experiment for an IR capsule.  This was not the case as shown with the research instrument 

























































compartment over 5 minutes from the time that capsule first ruptured helped to validate the 
analytical results.  The drug was slowly released from the capsule over time.  The GastroPlus 
simulation failed to consider this slow release of the drug over time through this rupture.   
 The research instrument data for the gastric compartment showed a slight dip from the 
first and second pull.  This was possibly caused by a delay in the full rupture of the capsule.  
Some of the drug was released before the excipients plugged up the rupture hole in the capsule 
shell.  Then the capsule disintegrated further allowing more material to be released over time.   
 The research instrument duodenum compartment results matched well with the 
GastroPlus simulation.  The slower uptake of amount recovered correlates to the slower release 
of the drug into the gastric compartment.  It was noted at the end of the experiment there was a 
negative analytical value obtained for the sixty-minute timepoint due to the subtraction of the 
placebo absorbance.  These results were based off the assumption of 100% capsule absorbance 
interference at each time point.  Further work would be needed to investigate the actual placebo 
absorbance interference throughout the run as the interference would degrade over time as the 
placebo material is passed onto the waste compartment.  
 The data from Compound C did not match with the GastroPlus simulation when using the 
parameters established with Compound T for the gastric compartment.  However, the differences 
noted in the gastric compartment help to illustrate why this research instrument could improve 
the predictive capability of GastroPlus.  The fact that GastroPlus simulation did not consider the 
actual release of the material into the gastric compartment over time led to an error of material 
being available in the duodenum compartment faster than observed.   
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In the end, the parameters in Chapter 2 are correct to be used to match with GastroPlus 
simulations.  The observations made during the actual experimental run related to the 
disintegration of the formulation over time plays the biggest role in seeing the differences 
between the GastroPlus simulation model and the results from the research instrument.   
As discussed in Chapter 1, the dissolution test is important as it is the only analytical test 
used that monitors the disintegration of the oral solid dosage and the dissolution of the active 
pharmaceutical ingredient in media.  This research instrument is proven to be able to measure 
both the disintegration of the oral solid dosage as well as the amount of drug released or 
available in both the gastric compartment and the duodenum compartment over time. 
3.5 Compound T Experiment with Higher Gastric pH and Sip of Water 
The research instruments running parameters from Chapter 2 were modified for this 
experiment to see the impact of the profiles for the gastric compartment and the duodenum 
compartment with the following differences to simulate an individual that had a higher stomach 
pH and used only a sip of water rather to take the medicine rather than a full glass.  The 
parameter differences were: 
• Gastric fluid and the fluid to be mixed with pH 5.0 Acetate buffer was 0.0001 N HCl.  
The pH of this media is 4.0. 
• The amount of DI water added at the start of the experiment was 15 mL rather than the 
240 mL for a full glass of water. 
• Due to the low volume of the water added, it was assumed that the gastric emptying event 
would not occur in the stomach.  Therefore, all transfer rates were kept at the lower 
steady state rates for the full length of the experiment. 
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Equations 3 and 6 in chapter 2.4 were used to calculate the volumes for each time point of 
this experiment because only the low transfer rates were used for the entire experiment.  The 
amount of drug recovered for each compartment at each time pulled was calculated and 
populated in Table 16.  The plots of the two compartments are seen in Figures 22 and 23.  
Table 16: Drug Recovery Results for Compound T, Higher Gastric pH and Sip Volume of Water 
Gastric Compartment Duodenum Compartment 
Time (Minutes) mg Recovered Time (Minutes) mg Recovered 
1:00 0.4225 
N/A 2:00 0.6219 3:00 0.6152 
4:16 0.5900 
5:00 0.5759 5:30 0.0275 
10:00 0.5429 10:30 0.0451 
15:00 0.4684 15:30 0.0560 
20:00 0.3826 20:30 0.0661 
25:00 0.3076 25:30 0.0837 
30:00 0.2448 30:30 0.0982 
60.00 0.0919 60:00 0.1215 
 
 






























Figure 23: Duodenum Compartment Results for Compound T, Higher Gastric pH and Sip 
Volume of Water 
 The data captured for this experiment assumed that the gastric emptying event would not 
occur when a sip of water was taken with the medication.  The volume in the stomach would not 
be great enough to have the event occur.  Therefore, transfer rates from each compartment were 
kept at the lower flow rates for the whole experiment. 
 With that assumption, the data depicts the importance of taking the medication with a full 
glass of water.  The drug was held up in the stomach longer than seen in previous experiments 
that had the gastric emptying event.  The drug did not have a large spike of the drug in the gastric 
compartment.  This could have been due to the higher pH being unable to disintegrate the tablet 
as quickly to deliver the large bolus of the drug up front as seen in the 0.01 N HCl media. 
 The duodenum compartment data showed a very low amount of the drug present 

























Compound T, 150 mL Duodenum Volume
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the gastric media was transferred to the duodenum compartment.  That related to approximately 
1.5% of the drug present in the gastric compartment being transferred to the duodenum 
compartment every minute.  In contrast, when the higher transfer rates are being applied the 
percent of the gastric media being transferred to the duodenum compartment starts at almost 6% 
and ends at just over 25%.  The larger volume being transferred relates to larger amount of the 
drug being transferred in the first 15 minutes with the gastric emptying event.  The consumption 
of the full glass of water to trigger the gastric emptying event is critical to move the drug to the 
duodenum compartment quickly.  
 The conclusion of this experiment is that a patient with a high gastric pH that took the 
medication with a sip of water would possibly result in the patient not feeling the full effect of 
the medication as it would not hit the efficacious dose in the body or the patient would have a 
longer delay in feeling the effects of the medication compared to a healthy individual who took 
the medication with a full glass of water and would have most of the drug in the duodenum 
compartment by 15 minutes based off of the Gastro Plus simulation and the experimental results 
displayed above. 
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Chapter 4.  Conclusion and Next Steps 
4.1 Conclusion  
A two-compartment dissolution research instrument with a reciprocating mixing 
technique was developed and validated for use with two compounds, Compound C and 
Compound T.  The instrument was designed to use bio relevant volumes and flow rates to mimic 
dosing in the fasted state.  The reciprocating mixing proved to be effective to eliminate effects of 
coning.  The peristaltic pumps demonstrated the ability to move solid particles from 
compartment to compartment, allowing undissolved drug to potentially pass through the system.   
The operating parameters for the two-compartment research instrument were modified to 
match GastroPlus simulations using Compound T.  These operating parameters were repeated 
using Compound T to demonstrate reproducibility of the results.  The operating parameters used 
for Compound T were applied to running Compound C on the research instrument to compare to 
the GastroPlus simulation prediction.  There were differences in the research instrument profiles 
for Compound C versus the GastroPlus simulation prediction.  This was explained due to a delay 
in the release of the drug after the capsule ruptured which was not accounted for in the 
GastroPlus simulation. 
The two-compartment research instrument was further tested by modifying the pH of the 
gastric compartment and adjusting the amount of water taken with the Compound T.  The reason 
for this experiment was to mimic the real-world situation of patients who have a higher gastric 
pH or patients who take acid reducing agents.  The assumption was that with a sip of water the 
gastric emptying event would not occur, and the low flow rates were used for the length of the 
experiment.  The resulting profiles were significantly different compared to the original results.  
This was a result of using the slower flow rates and the observations made that the tablet 
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disintegrated slower, possibly due to the higher pH of the gastric media.  This was an easy 
manipulation of the instrument that provided data showing the importance of taking a full glass 
of water with Compound T as well as the potential effects of the higher gastric pH on 
disintegrating the tablet, solubility and dissolution of the active pharmaceutical ingredient.  
4.2 Next Steps  
The instrument could be tested with higher dose drugs with low solubility.  This would 
allow the ability to see how much undissolved drug moves through the gastric and duodenum 
compartments.  It could also be possible to add on an additional compartment to simulate the 
intestinal fluids which would have much longer time points incorporated with that compartment. 
The instrument could be expanded for research purposes, rather than quality control 
testing, by exploring the FED state.  The fluids would need to include the appropriate fats and 
enzymes as seen in bio relevant media to simulate the gastric juices when food is present in the 
stomach.14-18 The enzymes could assist in disintegration of the oral solid dosage units.  For 
example, enzymes can play a role in preventing a known issue of crosslinking seen in the 
standard USP media for dissolution testing of gelatin capsules.10-11   
In the FED state the research instrument would need to have a food surrogate present in 
the mixing chamber.  The food would impart different forces, crushing and grinding, on the oral 
solid dosage unit than seen with this current version in the fasted state. This would be added 
forces applied to the dosage form that could be accounted for with further development of the 
mixing mechanism with semi soft beads added to the Gastric compartment to simulate the solid 
undigested food. 
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With the food surrogate present, the mixing mechanism of this research instrument would 
need to be revisited.  The sample holder would not allow the proper interaction of the food 
surrogate with oral dosage unit.  An instrument where a bag containing the food surrogate, 
biorelevant media, and the solid oral dosage unit that can be compressed at different angles could 
be one option to explore.   
Additional work could also be focused focus on adding absorption considerations for 
each compartment of the research instrument for research and development purposes.  One 
possible consideration for this experiment would be utilizing the Caco-2 continuous 
dissolution/Caco-2 system by Mark J. Ginski et al..32 The research had a pump from the 
dissolution vessel to the Caco-2 chamber as shown in Figure 8 below.  A similar concept could 
be used for this research instrument there by keeping the same mixing mechanism of the 
reciprocating cylinder as well as keeping the multi-compartment system. 
 
Figure 24: Schematic of the continuous dissolution/Caco-2 system32 
Lastly, the instrument itself can be better refined.  The transfer lines can move solid 
particles, but an improvement is needed to prevent the lines from being partially or fully blocked 
by solid particles during the test.  Better pumps for the transfer lines could be evaluated for more 
accurate flow rate calibrations.  The current pumps are calibrated prior to each experiment to 
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determine the transfer rates, but they do not exactly meet the target transfer rates.  A better 
engineered mechanism for controlling the travel distance of each cylinder would also help in 
making the instrument more robust from experiment to experiment.  This could be accomplished 
using by fabricating a straight arm metal pole inside a secondary metal tube with a stop arm to 
allow the accurate travel distance of the sample cylinder itself. 
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